Gawlewicz-Mroczka A - Search Results

1

Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma.

Mastalerz L, Gawlewicz-Mroczka A, Nizankowska E, Cmiel A, Szczeklik A. Mastalerz L, et al. Clin Exp Allergy. 2002 Sep;32(9):1360-5. doi: 10.1046/j.1365-2745.2002.01484.x. Clin Exp Allergy. 2002. PMID: 12220476 Clinical Trial.

2

Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity.

Mastalerz L, Sanak M, Gawlewicz-Mroczka A, Gielicz A, Cmiel A, Szczeklik A. Mastalerz L, et al. Thorax. 2008 Jan;63(1):27-34. doi: 10.1136/thx.2007.080903. Epub 2007 Jun 21. Thorax. 2008. PMID: 17584993 Clinical Trial.

3

Exhaled Eicosanoids following Bronchial Aspirin Challenge in Asthma Patients with and without Aspirin Hypersensitivity: The Pilot Study.

Mastalerz L, Sanak M, Kumik J, Gawlewicz-Mroczka A, Celejewska-Wójcik N, Cmiel A, Szczeklik A. Mastalerz L, et al. Among authors: gawlewicz mroczka a. J Allergy (Cairo). 2012;2012:696792. doi: 10.1155/2012/696792. Epub 2012 Jan 12. J Allergy (Cairo). 2012. PMID: 22291720 Free PMC article.

4

Machine learning in the diagnosis of asthma phenotypes during coronavirus disease 2019 pandemic.

Gawlewicz-Mroczka A, Pytlewski A, Celejewska-Wójcik N, Ćmiel A, Gielicz A, Sanak M, Mastalerz L. Gawlewicz-Mroczka A, et al. Clin Transl Allergy. 2022 Oct 19;12(10):e12201. doi: 10.1002/clt2.12201. eCollection 2022 Oct. Clin Transl Allergy. 2022. PMID: 36267429 Free PMC article.

5

Frequent exacerbators--a distinct phenotype of severe asthma.

Kupczyk M, ten Brinke A, Sterk PJ, Bel EH, Papi A, Chanez P, Nizankowska-Mogilnicka E, Gjomarkaj M, Gaga M, Brusselle G, Dahlén B, Dahlén SE; BIOAIR investigators. Kupczyk M, et al. Clin Exp Allergy. 2014 Feb;44(2):212-21. doi: 10.1111/cea.12179. Clin Exp Allergy. 2014. PMID: 24447083 Free article. Clinical Trial.

6

[Exercise-induced asthma; clinical presentation, pathogenesis and treatment].

Gawlewicz-Mroczka A, Mastalerz L, Nizankowska-Mogilnicka E. Gawlewicz-Mroczka A, et al. Pol Arch Med Wewn. 2004 Jun;111(6):721-6. Pol Arch Med Wewn. 2004. PMID: 15508796 Review. Polish. No abstract available.

7

[Prostaglandin E2: metabolism, determination in body fluids and the role in aspirin hypersensitivity].

Gawlewicz-Mroczka A, Gielicz A, Mastalerz L, Szczeklik A. Gawlewicz-Mroczka A, et al. Pol Arch Med Wewn. 2006 Jun;115(6):578-86. Pol Arch Med Wewn. 2006. PMID: 17263231 Review. Polish. No abstract available.

8

Omalizumab may decrease the thickness of the reticular basement membrane and fibronectin deposit in the bronchial mucosa of severe allergic asthmatics.

Zastrzeżyńska W, Przybyszowski M, Bazan-Socha S, Gawlewicz-Mroczka A, Sadowski P, Okoń K, Jakieła B, Plutecka H, Ćmiel A, Sładek K, Musiał J, Soja J. Zastrzeżyńska W, et al. Among authors: gawlewicz mroczka a. J Asthma. 2020 May;57(5):468-477. doi: 10.1080/02770903.2019.1585872. Epub 2019 Mar 23. J Asthma. 2020. PMID: 30905217 Clinical Trial.

9

Genetic polymorphisms of the novel FCERIA gene region: relation to total serum IgE levels.

Potaczek DP, Sanak M, Mastalerz L, Milewski M, Gawlewicz-Mroczka A, Szczeklik A. Potaczek DP, et al. Ann Allergy Asthma Immunol. 2007 May;98(5):500-1. doi: 10.1016/s1081-1206(10)60770-3. Ann Allergy Asthma Immunol. 2007. PMID: 17521040 No abstract available.

10

[Neurofibromatosis type 1 in an adult diagnosed by a pulmonologist].

Gawlewicz-Mroczka A, Mastalerz L, Nizankowska-Mogilnicka E. Gawlewicz-Mroczka A, et al. Pneumonol Alergol Pol. 2009;77(5):474-8. Pneumonol Alergol Pol. 2009. PMID: 19890828 Free article. Review. Polish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page